Answers are grounded in this paper and cite their sources.
To evaluate the long-term comparative efficacy of inebilizumab (INEB) over N-MOmentum open label period (OLP) vs azathioprine and other immunosuppressants (AZA/IST) and vs historical-placebo (PBO) in participants with neuromyelitis optica spectrum disorder (NMOSD).
No takes yet. Share an insight, caveat, or question.
Cree et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: